Hottest Stories: Big Lots (NYSE:BIG), Great Panther Silver (NYSEMKT:GPL), The Royal Bank of Scotland Group (NYSE:RBS), Marinus Pharmaceuticals (NASDAQ:MRNS), VolitionRX Ltd (NYSEMKT:VNRX)

Big Lots Inc. (NYSE:BIG) shares moved up 2.27% in last trading session and ended the day at $46.95. BIG Gross Margin is 39.70% and its has a return on assets of 8.20%. Big Lots Inc. (NYSE:BIG) quarterly performance is 2.49%.

Headquartered in Columbus, Ohio, Big Lots, Inc. (BIG) is a unique, non-traditional, discount retailer operating 1,463 BIG LOTS stores in 47 states with product assortments in the merchandise categories of Food, Consumables, Furniture, Seasonal, Soft Home, Hard Home, and Electronics & Accessories. Our vision is to be recognized for providing an outstanding shopping experience for our customers, valuing and developing our associates, and creating growth for our shareholders.

Big Lots, Inc. (NYSE:BIG) announced that, on August 27, 2015, our Board of Directors declared a quarterly cash dividend of $0.19 per common share. The dividend will be paid on September 25, 2015, to shareholders of record as of the close of business on September 11, 2015.

Great Panther Silver Ltd (NYSEMKT:GPL) ended the last trading day at $0.38. Company weekly volatility is calculated as 5.52% and price to cash ratio as 3.68. Great Panther Silver Ltd (NYSEMKT:GPL) showed a weekly performance of -5.31%.

Great Panther Silver Limited is a primary silver mining and exploration company listed on the Toronto Stock Exchange trading under the symbol GPR, and on the NYSE MKT trading under the symbol GPL.

On 28 August, GREAT PANTHER SILVER LIMITED (NYSE MKT: GPL) reported that its board of directors (the “Board”) has determined that it is not in the best interests of the Company to accept the resignation submitted by Jeffrey Mason, who was elected at the Company’s Annual General Meeting of Shareholders held on June 4, 2015. Mr. Mason did not receive the support of the majority of the votes cast at the meeting.

On 08 September, The Royal Bank of Scotland Group plc (NYSE:RBS) shares advanced 3.79% and was closed at $10.14. RBS EPS growth in last 5 year was 65.20%. The Royal Bank of Scotland Group plc (NYSE:RBS) year to date (YTD) performance is -16.27%.

The Royal Bank of Scotland Group plc (RBS) provides financial products and services to personal, commercial, corporate and institutional customers. The Company conducts its business through three franchises and seven operating segments. The Company’s Personal & Business Banking (PBB) franchise consists of two segments: UK Personal & Business Banking (UK PBB), including Williams & Glyn, and Ulster Bank.

The Royal Bank of Scotland Group plc (NYSE:RBS) is to switch from its paper money to polymer, following a lead set by its Scottish rivals. Clydesdale Bank and Bank of Scotland are already making the transition and the Bank of England is to introduce the plastic notes from next year. Royal Bank of Scotland said it was to re-design its notes with new subjects for portraits.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares fell -5.01% in last trading session and ended the day at $13.07. MRNS has a return on assets of -38.90%. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) quarterly performance is 6.43%.

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor.

VolitionRX Ltd (NYSEMKT:VNRX) caters to the Healthcare space. Its weekly performance is 25.75%. On the last day of trading company shares ended up $4.20. VolitionRX Ltd (NYSEMKT:VNRX) distance from 50-day simple moving average (SMA50) is 18.49%.
Zacks downgraded shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) from a buy rating to a hold rating in a research report sent to investors on Friday morning, Market Beat.com reports.

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx Limited (NYSE MKT: VNRX), announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the 17th Annual Rodman & Renshaw Global Investment Conference being held September 8-10, 2015 in New York, NY. In addition, VolitionRx’s Business Development Director, Dr. Mark Eccleston will be presenting at the CNAPS (Circulating Nucleic Acids in Plasma and Serum) IX Conference being held September 10-12 in Berlin, Germany. These conferences are attended by public companies, institutional investors, industry executives, scientists, private equity firms, private companies, venture capitalists, business development executives and sophisticated private investors.